乌司奴单抗的安全性和疗效评价。
Review of the safety and efficacy of ustekinumab.
机构信息
Jill Roberts Associate Professor of Clinical Medicine and Director of Jill Roberts Center for Inflammatory Bowel Disease, Weill Medical College of Cornell University/New York Presbyterian Hospital, 425 East 61st Street, 10th Floor, New York, NY 10021, USA.
出版信息
Therap Adv Gastroenterol. 2010 Sep;3(5):321-8. doi: 10.1177/1756283X10374216.
Abstract
Ustekinumab is a subcutaneously and intravenously administered fully human monoclonal immunoglobulin (IgG1) antibody targeting the interleukin (IL)-12/23 shared P40 subunit. The pivotal role of IL-12/23 inflammatory-mediated pathways is increasingly recognized in a plethora of immune-mediated inflammatory disorders including Crohn's disease, psoriasis, and multiple sclerosis. In a randomized controlled trial of ustekinumab in moderate-to-severe Crohn's disease, clinical response was achieved most notably in infliximab-experienced primary and secondary nonresponders and suboptimal responders.
摘要
乌司奴单抗是一种皮下和静脉注射用的全人源单克隆免疫球蛋白（IgG1）抗体，靶向白细胞介素（IL）-12/23 共用 P40 亚单位。IL-12/23 炎症介导途径的关键作用在包括克罗恩病、银屑病和多发性硬化症在内的多种免疫介导的炎症性疾病中得到了越来越多的认可。在乌司奴单抗治疗中重度克罗恩病的随机对照试验中，临床应答主要见于英夫利昔单抗初治和既往治疗的原发性和继发性无应答者以及应答欠佳者。
相似文献
1
Review of the safety and efficacy of ustekinumab.
Therap Adv Gastroenterol. 2010 Sep;3(5):321-8. doi: 10.1177/1756283X10374216.
2
Update on ustekinumab for the treatment of Crohn's disease.
Gastroenterol Clin North Am. 2014 Sep;43(3):619-30. doi: 10.1016/j.gtc.2014.05.013.
3
Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Cochrane Database Syst Rev. 2019 Dec 12;12(12):CD012804. doi: 10.1002/14651858.CD012804.pub2.
4
Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement.
Patient Prefer Adherence. 2013 Apr 26;7:369-77. doi: 10.2147/PPA.S33162. Print 2013.
5
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
Gastroenterology. 2008 Oct;135(4):1130-41. doi: 10.1053/j.gastro.2008.07.014. Epub 2008 Jul 17.
7
Clinical utility of ustekinumab in Crohn's disease.
J Inflamm Res. 2018 Feb 8;11:35-47. doi: 10.2147/JIR.S157358. eCollection 2018.
8
Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
Drug Des Devel Ther. 2016 Nov 11;10:3685-3698. doi: 10.2147/DDDT.S102141. eCollection 2016.
9
Next generation of biologics for the treatment of Crohn's disease: an evidence-based review on ustekinumab.
Clin Exp Gastroenterol. 2017 Nov 15;10:293-301. doi: 10.2147/CEG.S110546. eCollection 2017.
10
Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.
Clin Exp Gastroenterol. 2014 May 23;7:173-9. doi: 10.2147/CEG.S39518. eCollection 2014.
引用本文的文献
1
Biologics and Small Molecules for Inflammatory Nail Disorders: A Narrative Review.
Indian Dermatol Online J. 2024 Dec 26;16(1):50-58. doi: 10.4103/idoj.idoj_445_24. eCollection 2025 Jan-Feb.
2
Case Report: Malignant melanoma in a patient with Crohn's disease treated with ustekinumab.
F1000Res. 2023 Oct 4;11:424. doi: 10.12688/f1000research.110356.2. eCollection 2022.
3
Vedolizumab-induced acute interstitial nephritis with failure of steroid prophylaxis on vedolizumab rechallenge.
BMJ Case Rep. 2023 Sep 12;16(9):e254715. doi: 10.1136/bcr-2023-254715.
4
Alopecia Areata: Current Treatments and New Directions.
Am J Clin Dermatol. 2023 Nov;24(6):895-912. doi: 10.1007/s40257-023-00808-1. Epub 2023 Aug 22.
5
Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?
Drugs R D. 2021 Sep;21(3):341-350. doi: 10.1007/s40268-021-00349-0. Epub 2021 Jun 9.
6
Ustekinumab-induced chronic lymphocytic leukemia in a patient with psoriatic arthritis.
Reumatologia. 2021;59(1):58-61. doi: 10.5114/reum.2021.102618. Epub 2021 Feb 28.
7
New and Emerging Therapies for Alopecia Areata.
Drugs. 2020 May;80(7):635-646. doi: 10.1007/s40265-020-01293-0.
8
Ustekinumab for the treatment of refractory pediatric Crohn's disease: a single-center experience.
Intest Res. 2021 Apr;19(2):217-224. doi: 10.5217/ir.2019.09164. Epub 2020 Apr 22.
9
Ustekinumab in Crohn's disease: evidence to date and place in therapy.
Ther Adv Chronic Dis. 2016 Jul;7(4):208-14. doi: 10.1177/2040622316653306. Epub 2016 Jul 6.
10
Ustekinumab for the treatment of Crohn's disease: can it find its niche?
Therap Adv Gastroenterol. 2016 Jan;9(1):26-36. doi: 10.1177/1756283X15618130.
本文引用的文献
1
Inflammatory bowel disease.
N Engl J Med. 2009 Nov 19;361(21):2066-78. doi: 10.1056/NEJMra0804647.
2
Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease.
Inflamm Bowel Dis. 2010 Jul;16(7):1209-18. doi: 10.1002/ibd.21159.
3
Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease.
Am J Gastroenterol. 2009 Nov;104(11):2768-73. doi: 10.1038/ajg.2009.454. Epub 2009 Aug 11.
4
Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis.
Arthritis Res Ther. 2008;10(5):R122. doi: 10.1186/ar2530. Epub 2008 Oct 13.
5
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
Gastroenterology. 2008 Oct;135(4):1130-41. doi: 10.1053/j.gastro.2008.07.014. Epub 2008 Jul 17.
6
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
Lancet Neurol. 2008 Sep;7(9):796-804. doi: 10.1016/S1474-4422(08)70173-X.
7
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease.
Nat Genet. 2008 Aug;40(8):955-62. doi: 10.1038/ng.175. Epub 2008 Jun 29.
8
The genetics and immunopathogenesis of inflammatory bowel disease.
Nat Rev Immunol. 2008 Jun;8(6):458-66. doi: 10.1038/nri2340.
9
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Lancet. 2008 May 17;371(9625):1675-84. doi: 10.1016/S0140-6736(08)60726-6.
10
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Lancet. 2008 May 17;371(9625):1665-74. doi: 10.1016/S0140-6736(08)60725-4.
Zotero 插件